Ligand Pharmaceuticals Incorporated (LGND) Financial Analysis & Valuation | Quarter Chart

Ligand Pharmaceuticals Incorporated (LGND)

LGND
Price: $314.04
Fair Value: 🔒
🔒score
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury fo... more
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring... more
Description Shares
Market Cap$6.29BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOTodd C. Davis
IPO Date1992-11-18CAGR0.1%
Employees68Websitewww.ligand.com
Div. Yield—Payout Ratio—
Buy Back Yield0.18%Total Yield0.18%
LGND chart loading...
Fundamentals Technicals
Enterprise Value$5.88BP/E Ratio37.65
Forward P/E27.75PEG Ratio—
P/S Ratio30.67P/B Ratio8.37
P/CF Ratio67.67P/FCF Ratio68.47
EPS$8.34EPS Growth 1Y—
EPS Growth 3Y484.92%EPS Growth 5Y220.43%
Revenue Growth 1Y51.24%Gross Margin0.99%
Operating Margin0.37%Profit Margin0.56%
ROE0.16%ROA0.1%
ROCE0.07%Current Ratio21.28
Quick Ratio20.95Cash Ratio2.83
Debt/Equity0.45Interest Coverage87.41
Altman Z Score8.79Piotroski Score6

View Ligand Pharmaceuticals Incorporated financial charts →